Treating transcriptional addiction in small cell lung cancer

Arnaud Augert; David MacPherson

doi:10.1016/j.ccell.2014.11.012

Treating transcriptional addiction in small cell lung cancer

Cancer Cell. 2014 Dec 8;26(6):783-784. doi: 10.1016/j.ccell.2014.11.012.

Authors

Arnaud Augert¹, David MacPherson²

Affiliations

¹ Divisions of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
² Divisions of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. Electronic address: dmacpher@fhcrc.org.

PMID: 25490443
DOI: 10.1016/j.ccell.2014.11.012

Abstract

Small cell lung cancer (SCLC) is a devastating tumor type with great therapeutic need. In this issue of Cancer Cell, Christensen and colleagues identify THZ1, a CDK7 inhibitor, as a potential therapy for SCLC. Using cells and mouse models, the authors show exquisite sensitivity of SCLC to transcriptional inhibition.

Publication types

Comment

MeSH terms

Animals
Antineoplastic Agents / administration & dosage*
Enzyme Inhibitors / administration & dosage*
Gene Expression Regulation, Neoplastic / drug effects*
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics*
Transcription Factors / metabolism*

Substances

Antineoplastic Agents
Enzyme Inhibitors
Transcription Factors